Fellenberg J, Mau H, Scheuerpflug C, Ewerbeck V, Debatin K M
Stiftung Orthopädische Universitätsklinik Heidelberg, Germany.
Int J Cancer. 1997 Jul 29;72(3):536-42. doi: 10.1002/(sici)1097-0215(19970729)72:3<536::aid-ijc25>3.0.co;2-8.
The CD95/APO-1 Fas receptor/ligand system plays a crucial role in growth control by mediating apoptosis in lymphoid and non-lymphoid cells. To investigate the role of CD95-mediated apoptosis in osteosarcoma, we studied 3 human osteosarcoma cell lines (HOS/TE 85, MG 63 and Saos-2) and osteoblasts derived from bone biopsies. In contrast to osteoblast-like cells, all cell lines were resistant to anti-APO-1-induced apoptosis despite constitutive CD95 expression at intermediate levels. Blocking of macromolecular synthesis by cycloheximide or actinomycin D or modulation of CD95 expression by cytokines (TNF-alpha and/or gamma-interferon) restored sensitivity to anti-APO-1-induced cell death. PCR analysis of the CD95 transcripts revealed the production of a truncated splice variant that codes for a soluble form of the CD95 receptor. Synthesis and secretion of soluble CD95 protein into the culture supernatant was demonstrated by Western blot analysis. Treatment with sensitizing cytokines led to up-regulation of full-length CD95 transcripts and the encoded membrane-bound CD95 protein but not the truncated mRNA splice variant and the corresponding soluble receptor, as shown by PCR and Western blot analysis. The biological activity of soluble CD95 secreted by osteosarcoma cells was demonstrated by the ability of osteosarcoma supernatants to protect the sensitive T-cell line Jurkat from anti-APO-1-mediated apoptosis. Our results suggest that the production of soluble CD95 by osteosarcoma cell lines that may block physiological death signals and the production of membrane-bound CD95 are differently regulated by cytokines via modulation of RNA splicing.
CD95/APO-1 Fas受体/配体系统通过介导淋巴细胞和非淋巴细胞的凋亡在生长控制中起关键作用。为了研究CD95介导的凋亡在骨肉瘤中的作用,我们研究了3种人骨肉瘤细胞系(HOS/TE 85、MG 63和Saos-2)以及来自骨活检的成骨细胞。与成骨样细胞不同,尽管所有细胞系在中等水平组成性表达CD95,但它们都对抗APO-1诱导的凋亡具有抗性。用放线菌酮或放线菌素D阻断大分子合成或用细胞因子(肿瘤坏死因子-α和/或γ-干扰素)调节CD95表达可恢复对抗APO-1诱导的细胞死亡的敏感性。对CD95转录本的PCR分析揭示了一种截短的剪接变体的产生,该变体编码CD95受体的可溶性形式。通过蛋白质印迹分析证实了可溶性CD95蛋白合成并分泌到培养上清液中。如PCR和蛋白质印迹分析所示,用致敏细胞因子处理导致全长CD95转录本和编码的膜结合CD95蛋白上调,但截短的mRNA剪接变体和相应的可溶性受体没有上调。骨肉瘤细胞分泌的可溶性CD95的生物学活性通过骨肉瘤上清液保护敏感T细胞系Jurkat免受抗APO-1介导的凋亡的能力得以证明。我们的结果表明,骨肉瘤细胞系产生的可溶性CD95可能阻断生理死亡信号,并且膜结合CD95的产生受细胞因子通过RNA剪接的调节而有所不同。